Plandai Biotechnology (Plandai Biotechnology) Cash-to-Debt : 0.00 (As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Plandai Biotechnology Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Plandai Biotechnology's cash to debt ratio for the quarter that ended in Jun. 2023 was 0.00.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Plandai Biotechnology couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for Plandai Biotechnology's Cash-to-Debt or its related term are showing as below:

During the past 13 years, Plandai Biotechnology's highest Cash to Debt Ratio was 0.01. The lowest was 0.00. And the median was 0.00.

PLPL's Cash-to-Debt is not ranked ^*
in the Diversified Financial Services industry.
Industry Median: 5.385
* Ranked among companies with meaningful Cash-to-Debt only.

Plandai Biotechnology Cash-to-Debt Historical Data

The historical data trend for Plandai Biotechnology's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Plandai Biotechnology Cash-to-Debt Chart

Plandai Biotechnology Annual Data

Trend

Mar09

Mar10

Mar11

Jun12

Jun13

Jun14

Jun15

Jun16

Jun22

Jun23

Cash-to-Debt

Get a 7-Day Free Trial

0.01

Plandai Biotechnology Semi-Annual Data
	Mar03	Mar04	Mar05	Mar06	Mar07	Mar08	Mar09	Mar10	Mar11	Jun12	Jun13	Jun14	Jun15	Jun16	Jun22	Jun23
Cash-to-Debt	Get a 7-Day Free Trial											0.01	-	-	-	-

Competitive Comparison of Plandai Biotechnology's Cash-to-Debt

For the Shell Companies subindustry, Plandai Biotechnology's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Plandai Biotechnology's Cash-to-Debt Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Plandai Biotechnology's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Plandai Biotechnology's Cash-to-Debt falls into.

Plandai Biotechnology Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Plandai Biotechnology's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0	/	(0.05	+	0)
	=	0.00

Plandai Biotechnology's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0	/	(0.05	+	0)
	=	0.00

Plandai Biotechnology (OTCPK:PLPL) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Plandai Biotechnology Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Plandai Biotechnology's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Plandai Biotechnology (Plandai Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Plandai Biotechnology Inc (OTCPK:PLPL) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

4811 49th Street, San Diego, CA, USA, 92115

Website

http://www.plandaibiotech.com

Plandai Biotechnology Inc. manufactures highly bioavailable extracts from live plant materials.

Executives

Callum Baylis-duffield	director	FLAT 37 ISLAND HOUSE THREE MILL LANE, LONDON ENGLAND X0 E33AF
Timothy Matula	other: Former Director	175 JACKSON AVE N, SUITE 102, MINNEAPOLIS MN 55343
Brian Johnson	director	P.O. BOX 1594, FERNDALE WA 98248-1594
Roger Duffield	director, officer: President, Secretary and CFO	2226 EASTLAKE AVENUE EAST #156, SEATTLE WA 98102
Daron Baylis Duffield	director	2226 EASTLAKE AVENUE EAST #156, SEATTLE WA 98102
David Rzepnicki	director	21 HORIZON DRIVE, SARATOGA SPRINGS NY 12866